There is a well-established heterogeneity in BC subtypes with presence, absence or a combination of estrogen receptor alpha (ERɑ), human epidermal growth factor receptor (HER2) and progesterone receptors (PR), that dictate treatment strategies. The gene discussed is ERBB2; the disease is breast cancer.